www.toulousainrugby.com • Professional Insights • Expert Commentary • Resource Center
www.toulousainrugby.com

Review Breakdown,selectively bind to KRAS protein

Kras Cyclic Peptide: A Novel Frontier in Targeted Cancer Therapy 26 Jul 2023—Cyclic peptidesas a therapeutic modality are attracting a lot of attention due to their potential for oral absorption and accessibility to 

:They cycle between GDP-bound inactive state and a GTP-bound (active) form

A
Joan Ellis

studies '' user interaction and behavior trends and provides detailed analysis through X (Twitter) and Medium

Published on

Executive Summary

K-Ras 26 Jul 2023—Cyclic peptidesas a therapeutic modality are attracting a lot of attention due to their potential for oral absorption and accessibility to 

The intricate world of cancer research is constantly seeking innovative therapeutic strategies, and kras cyclic peptide represents a promising new avenue. These specialized molecules are gaining significant attention for their potential to precisely target and inhibit the KRAS protein, a key player in the development and progression of numerous cancers. Understanding the structure, function, and therapeutic applications of kras cyclic peptide is crucial for appreciating its impact on the future of oncology.

KRAS, a member of the RAS protein family, is a GTPase that plays a central role in regulating cell signaling pathways involved in cell growth and survival. Mutations in the KRAS gene are among the most common genetic alterations found in human cancers, with KRAS being the most mutated protein in the RAS family, accounting for approximately 85% of RAS oncogenic mutations. The most prevalent mutation, K-Ras(G12D), significantly disrupts normal cellular processes, leading to uncontrolled cell proliferation. This underscores the critical need for therapies that can specifically address these mutated forms.

Cyclic peptides offer a unique advantage in targeting proteins like KRAS. Unlike linear peptides, their circular structure provides enhanced stability against enzymatic degradation and improved binding affinity to their targets. This structural characteristic makes them well-suited for exploiting the hydrophobic interface features of protein-protein interactions, a hallmark of KRAS signaling. Furthermore, cyclic peptides can exhibit antibody-like efficacy, offering a potent and specific therapeutic modality. Research has focused on developing cyclic peptides that can selectively bind to KRAS protein and disrupt its aberrant signaling.

A significant breakthrough in this field was the discovery of KRpep-2d, an artificial cyclic peptide, in 2017. KRpep-2d was identified as the first selective inhibitor of K-Ras(G12D), the most frequent K-Ras mutation. This arginine-rich KRAS-binding peptide features a disulfide-mediated macrocyclic linkage and a protease-sensitive backbone, contributing to its efficacy. Studies have demonstrated that KRpep-2d can selectively bind to the G12D mutant of K-Ras, which is a key member of the Ras protein family. The crystal structure of a human K-Ras G12D mutant in complex with KRpep-2d has been elucidated, providing valuable insights into its mechanism of action.

Further development has led to the identification of other promising kras cyclic peptide candidates. For instance, GTP-state-selective cyclic peptide ligands of K-Ras(G12D) have been developed that show preferential binding to the GTP-bound state of K-Ras(G12D) over the GDP-bound state. This selectivity is crucial because KRAS proteins cycle between GDP-bound inactive state and a GTP-bound (active) form. By targeting the active, GTP-bound state, these cyclic peptides can effectively block downstream signaling. Specifically, these cyclic peptides have been shown to block the Ras-Raf interaction, a critical step in the KRAS signaling pathway. Research also indicates that these cyclic peptides can attenuate the interaction between KRAS and the BRAF RAS-binding domain, thereby inhibiting oncogenic signaling.

The therapeutic potential of kras cyclic peptide extends to their ability to be developed into orally bioavailable drugs. This is a significant advantage over many traditional protein-targeting therapies that require intravenous administration. The compound luna18, a Kras cyclic peptide, has shown therapeutic potential as an oral drug for the treatment of various cancers. Clinical trials, such as Roche's Phase I trial of Oral Cyclic Peptide KRAS inhibitor Luna18, are actively investigating the safety and efficacy of such compounds. The development of orally bioavailable peptides targeting KRAS is a major step towards more convenient and accessible cancer treatments.

Beyond KRpep-2d and luna18, other research efforts are exploring different classes of kras cyclic peptide. For example, DIRAS3-derived cyclic peptides have been shown to disrupt KRAS-RAF interactions by attenuating the interaction between KRAS and the BRAF RAS-binding domain, and they can penetrate cells efficiently to inhibit KRAS signaling. Furthermore, macrocyclic peptides are being investigated for their ability to disrupt previously intractable protein-protein interactions relevant to oncology.

The development of kras cyclic peptide is a testament to the power of advanced molecular design and targeted drug discovery. By creating polypeptide chains which contain a circular sequence of bonds, researchers are developing molecules with enhanced stability, specificity, and therapeutic efficacy. These cyclic peptides represent a significant advancement in the fight against Ras mutant cancer, offering hope for more effective and less toxic treatments. The ongoing research, including the exploration of KRAS G12D Peptide variants and the identification of peptide inhibitors of KRAS G12D and Q61H mutations, suggests a bright future for kras cyclic peptide in precision oncology.

Related Articles

Frequently Asked Questions

Here are the most common questions about .

by S Lim·2021·Cited by 31—We focused on KRpep-2d,an arginine-rich KRAS-binding peptidewith a disulfide-mediated macrocyclic linkage and a protease-sensitive backbone.
Structure-activity relationships of middle-size cyclic
Development of Orally Bioavailable Peptides Targeting an
Cyclic peptides arepolypeptide chains which contain a circular sequence of bonds. This can be through a connection between the amino and carboxyl ends of 

Leave a Comment

Share your thoughts, feedback, or additional insights on this topic.

Explore More